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Abstract
Notwithstanding remarkable progress in vascular network engineering, implanted bioengineered 
microvessels largely fail to form anastomoses with the host vasculature. Here, we demonstrate that 
implants containing assembled human vascular networks (A-Grafts) fail to engraft due to their 
inability to engage non-inflammatory host neutrophils upon implantation into mice. In contrast, 
unassembled vascular cells (U-Grafts) readily engage alternatively polarized neutrophils, which in 
turn serve as indispensable mediators of vascular assembly and anastomosis. The depletion of host 
neutrophils abrogated vascularization in U-Grafts, whereas an adoptive transfer of neutrophils 
fully restored vascularization in myeloid-depleted mice. Neutrophil engagement was regulated by 
secreted factors and was progressively silenced as the vasculature matured. Exogenous addition of 
factors from U-Grafts reengaged neutrophils and enhanced revascularization in A-Grafts, a process 
that was recapitulated by blocking Notch signaling. Our data suggest that the pro-vascularization 
potential of neutrophils can be harnessed to improve the engraftment of bioengineered tissues.
Tissue engineering holds great promise in regenerative medicine as a solution to the 
increasing demand for donor organs and tissues 1. In this context, bioengineering functional 
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vascular networks is central 2,3. The last decade has seen remarkable progress in our 
collective effort to bioengineer such networks by self-assembly of vascular cells within 
suitable biomaterials 4–9. However, efforts remain mostly empirical due in large part to the 
inability of bioengineered microvessels to connect to the host circulatory system upon 
implantation. This challenge is similar to that of primary tissues during surgical 
grafting 10–14. Indeed, clinical experience with primary tissues has repeatedly shown that 
inadequate revascularization remains a common outcome, leading to various degrees of graft 
resorption and failure 15,16. Therefore, the search for new approaches to advance graft 
revascularization continues to be a pressing priority in regenerative medicine.
Previous studies have shown that adult neovascularization and angiogenesis rely on myeloid 
cells 17,18. Efforts have been primarily focused on the effects of monocytes and macrophages 
on tumor angiogenesis 19–21. Nevertheless, studies have also established a prominent role for 
neutrophils in tumor angiogenesis 22–24. In grafting models, studies have collectively 
demonstrated that transplanted hypoxic tissues recruit proangiogenic matrix 
metalloproteinase (MMP)-9-delivering neutrophils in a vascular endothelial growth factor 
(VEGF)-dependent manner and that inhibiting neutrophil recruitment impairs in growth of 
host vessels into the grafts 25,26. In bioengineered grafts, however, the contribution of 
neutrophils is largely unknown.
In this study, we sought to determine the extent to which host myeloid cells, in general, and 
neutrophils, in particular, govern the engraftment of bioengineered vascular networks. To 
this end, we examined microvasculatures at two contrasting states of maturation. On one 
hand, we bioengineered graft containing fully-assembled vascular networks embedded in 3-
dimensional hydrogel constructs (referred to as assembled grafts or A-grafts). These 
vascular networks mimicked the indolent state of mature microvessels and thus largely failed 
to spontaneously connect with the host circulation upon implantation. On the other hand, we 
bioengineered grafts that simply contained an unassembled suspension of vascular cells 
embedded in a hydrogel (referred to as unassembled grafts or U-Grafts), configuration that 
we have previously shown to effectively produce perfused networks of microvessels 
following implantation 27,28. By comparing these two distinct graft models, we found that 
the inefficient engraftment of A-grafts was due to the inherent inability of their mature 
microvasculature to engage non-inflammatory host neutrophils, which in U-Grafts served as 
indispensable mediators of vascularization.
RESULTS
Inefficient engraftment of bioengineered human microvessels
To evaluate engraftment of bioengineered microvessels, we generated grafts containing 
fully-assembled vascular networks embedded in 3-dimensional constructs (A-grafts). In 
addition, we prepared grafts that simply contained an unassembled suspension of the same 
vascular cells (U-Grafts) (Fig. 1a). In both cases, grafts were prepared in vitro by combining 
human endothelial colony-forming cells (ECFCs) with mesenchymal stem cells (MSCs) 
(4x105 cells; 1:1 ratio) in gelatin-based hydrogels (GelMA) that were previously shown to 
be compatible with vascular morphogenesis 5,28. U-Grafts were suspensions of the cells in 
the hydrogel at day 0, whereas A-grafts were formed by letting the ECFCs to self-assemble 
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into mature networks over 7 days in vitro (Fig. 1a). We studied the engraftment of both types 
of grafts following subcutaneous implantation into nude mice. After 7 days in vivo, U-Grafts 
contained an extensive network of perfused microvessels (Fig. 1b). Their lumens expressed 
h-CD31, confirming the human nature of the endothelium (Fig. 1c), and carried murine 
erythrocytes, indicating connection with the host circulatory system (Fig. 1b,c; 
Supplementary Fig. 1). In contrast, the number of perfused human vessels in A-Grafts was 
insignificant (Fig. 1d). Instead, the ECFCs remained organized as cellular cords but were 
rarely perfused (Fig. 1b,c). This lack of anastomosis formation by pre-assembled vessels in 
A-Grafts recapitulated the indolent state observed in the microvasculature of transplanted 
primary tissues (both murine and human) (Supplementary Fig. 2,3). Thus, this A-Graft/U-
Graft model was deemed suitable to study the mechanisms regulating engraftment of a 
bioengineered vascular network in the absence of tissue parenchyma.
Host neutrophils are indispensable for vascularization
Previously, we recognized that host myeloid cells participate in the vascularization of U-
Grafts 29. In addition, we showed that the hydrogel material used in our grafts is not 
immunoisolating and that host myeloid cells, including neutrophils, can freely invade our 
constructs 28. However, the mechanisms of action and the specific nature of these myeloid 
subpopulations had yet to be elucidated. Moreover, the role of myeloid cells in the 
engraftment of A-Grafts was completely unknown. Here, we identified a dynamic presence 
of three distinct host myeloid subpopulations in U-Grafts: 1) lymphocyte antigen 6 complex, 
locus G (Ly6G)-/F4/80hi macrophages; 2) Ly6G-/F4/80dim monocytes; and 3) Ly6G+ 
neutrophils (Supplementary Fig. 4; Fig. 1e). Neutrophil levels peaked prior to the onset of 
perfusion (~6x106 cells/graft at day 2) and then progressively faded as U-Grafts got 
vascularized, whereas macrophages peaked around day 3 (~3x106 cells/graft) and then 
remained moderately constant (Fig. 1e). Of note, there was a spatially uniform lack of both 
Ly6G+ neutrophils and macrophages throughout A-Grafts, which was in clear contrast to the 
abundant presence found in U-Grafts (Fig. 1f–h).
To examine the role myeloid cells in U-Grafts, we devised two separate strategies to deplete 
either circulating monocytes (α-F4/80 treatment) or neutrophils (α-Ly6G) in recipient mice 
(Fig. 2a,b; Supplementary Fig. 4). Depletion of circulating monocytes had no significant 
effect on vascularization; U-Grafts implanted into α-F4/80-treated mice displayed a 
microvascular density similar to the control group (140.7 ± 30.3 vessels/mm2 vs. 195.6 
± 19.7 vessels/mm2 in IgG-treated mice) (Fig. 2c,d). In contrast, depletion of neutrophils 
was detrimental to vascularization; U-Grafts implanted into α-Ly6G-treated mice had a 
reduced presence of perfused vessels at day 7 (Fig. 2c) and microvascular density was 
significantly lower (50.2 ± 6.7 vessels/mm2) than in the control group (Fig. 2d).
To confirm the pivotal role of neutrophils, we devised an adoptive transfer approach with 
irradiated mice (radiation effectively depleted >90% circulating myeloid cells for over a 
week, but it was not lethal; Supplementary Fig. 5). Briefly, U-Grafts were implanted into 
irradiated mice with or without a transfer of neutrophils from non-irradiated donor mice 
(Fig. 2e). Transferred neutrophils were an enriched population of mCD11b+/mLy6G+ cells 
(~95%; Supplementary Fig. 6) obtained with a neutrophil selection kit. U-Grafts implanted 
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into irradiated mice completely failed to vascularize; however, an adoptive transfer of bone 
marrow (BM)-derived mLy6G+ cells fully rescued vascularization, enabling formation of 
extensive networks of perfused blood vessels (Fig. 2f–i). Transfer of blood-derived mLy6G+ 
cells also rescued vascularization, although to a lesser extent (Fig. 2i). Of note, transfer of 
BM-derived F4/80+ cells (i.e., monocytes/macrophages) failed to rescue vascularization 
(Fig. 2f,i; Supplementary Fig. 7), which underscored the distinctive capability of 
neutrophils. Collectively, these results confirmed that host mLy6G+ neutrophils are 
indispensable for vascularization in implanted U-Grafts.
Vascularization of U-Grafts in immune-competent mice
To validate the dependency of graft vascularization on host neutrophils in immune-
competent hosts, we generated unassembled U-Grafts using murine autologous endothelial 
cells (ECs) and MSCs isolated from C57BL/6 mice (cells referred to as mECs and mMSCs) 
(Fig. 3a). These murine cells were isolated from excised subcutaneous tissues that were 
enzymatically digested and cells were purified by using magnetic beads with antibodies 
against murine CD31 (for mECs) and platelet-derived growth factor receptor-beta 
(PDGFRβ) (for mMSCs) via magnetic-activated cell sorting (MACS). Purified mECs and 
mMSCs were expanded in culture and their phenotype and purity were confirmed, as we 
previously described 30. Murine mECs were transduced to express green fluorescent protein 
(GFP) (referred to as GFP-mECs) and combined with mMSCs to generate U-Grafts, which 
were then subcutaneously implanted into immunocompetent C57BL/6 mice. Implants were 
harvested at day 7 and histological (hematoxylin and eosin, H&E) examination revealed that 
extensive networks of blood microvessels had formed and contained murine erythrocytes, 
confirming perfusion (Fig. 3b,c). Microvessels were lined by the implanted GFP-mECs as 
confirmed by GFP immunostaining (Fig. 3e). In addition, GFP+ microvessels were largely 
covered by alpha-smooth muscle actin (α-SMA)-expressing perivascular cells, indicating 
stability (Fig. 3e). Taken together, these data demonstrated that U-Grafts containing murine 
cells (mECs+mMSCs) can form microvascular networks in fully immune-competent hosts 
(C57BL/6 mice).
Next, we examined whether neutrophils were also indispensable for vascularization in 
immune-competent hosts (Fig. 3b). As in the previous xenograft model, depletion of 
neutrophils was also detrimental on vascularization in syngeneic grafts; murine U-Grafts 
implanted into α-Ly6G-treated C57BL/6 mice completely lacked perfused vessels (neither 
donor nor host) at day 7 (Fig. 3c,e) and microvascular density was negligible and 
significantly lower (1.4 ± 1.3 vessels/mm2) than in the control group (95.6 ± 4 vessels/mm2) 
(Fig. 3d).
In addition, we examined the presence of lymphocytes in murine U-Grafts implanted into 
immune-competent C57BL/6 hosts. To this end, grafts were explanted at day 2, 
enzymatically digested, and the retrieved cells were analyzed by flow cytometry. We 
examined the presence of mCD45+/mCD19+ B cells and mCD45+/mCD3+ T cells and 
found that the presence of both B and T cells in the grafts was minimal (<0.2%) and 
certainly significantly lower than the myeloid contribution (mCD11b+ cells were ~56.7% at 
day 2 in syngeneic murine U-Grafts implanted into C57BL/6) (Fig. 3f). Indeed, U-Grafts 
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implanted into α-Ly6G-treated mice failed to vascularize despite normal levels of circulating 
lymphocytes.
In summary, we demonstrated that 1) syngeneic murine U-Grafts did vascularize in immune-
competent host; 2) neutrophil participation was critical for the vascularization of syngeneic 
U-Grafts; and 3) lymphocyte presence in the grafts was minimal.
Alternatively polarized neutrophils mediate vascularization
Recent evidence suggest that neutrophils can acquire an alternative non-inflammatory 
phenotype (referred to as “N2”) that mediates tissue remodeling 31. Here, we compared 
neutrophils retrieved from explanted U-Grafts to inflammatory neutrophils isolated from 
lipopolysaccharide (LPS)-containing plugs (Fig. 4a). Neutrophils in U-Grafts did not 
resemble LPS-activated neutrophils in several respects, including (1) lower mRNA 
expression of canonical pro-inflammatory genes (namely, Ccl2, Ccl5, F4/80, Tnf, Itgam, 
Csf1, Icam1, Fas, and Il1rn); (2) higher expression of anti-inflammatory (Arg1, Il4) and pro-
remodeling (Vegfa, Pmepa1, Tgfbi) genes (Fig. 4b); and (3) lower phagocytic activity (Fig. 
4c). Previous studies have shown that N2 polarization is mediated via transforming growth 
factor-beta (TGFβ) signaling 31. To elucidate the potential role of TGFβ, we adoptively 
transferred neutrophils lacking TGFβ receptor 2 (tgfbr2−/−; from LysM-Cre::tgfbr2/loxP 
donors) into myeloid-depleted (irradiated) nude mice and examined the ability of U-Grafts 
to vascularize (Fig. 4d–g). Tgfbr2−/− neutrophils were not capable of restoring 
vascularization to the same extent as control neutrophils (34.7 ± 15.9 vessels/mm2 vs. 100.2 
± 11 vessels/mm2 with control LysM-Cre neutrophils) (Fig. 4g), indicating that the pro-
vascularization potential of neutrophils was dependent on tgfbr2 expression. To further 
confirm the need for TGFβ signaling, we evaluated the vascularization potential of U-Grafts 
in mice daily treated with SB432542, a potent and selective inhibitor of the TGF-β type I 
receptor. We found that treatment with SB432542 impaired the formation of perfused 
vascular networks. Indeed, the number of perfused vessels at day 7 in U-Grafts from 
SB432542-treated mice was insignificant (Fig. 4j); ECFCs appeared organized as cellular 
cords, but these cords were rarely perfused (Fig. 4h,i).
Taken together, our results show that U-Graft’s neutrophils distinctively displayed a non-
inflammatory phenotype that was consistent with the N2 phenotype; this alternative 
polarization was dependent on TGFβR/TGFβ signaling, and in turn was essential for 
neutrophil pro-vascularization function. Moreover, blocking TGFβ signaling via exogenous 
provision of SB432542 completely abrogated U-Graft vascularization.
Neutrophils activity is regulated by secreted factors
To gain further insight into how grafts engage host neutrophils, we collected daily samples 
of conditioned media (CM) from U-Grafts over 8 days in vitro (i.e., until they became A-
Grafts) (Fig. 5a). Subcutaneous plugs containing CM from U-Grafts robustly recruited 
neutrophils in nude mice (Fig. 5b) - note that neutrophil recruitment by CM(U-Grafts) was 
significantly higher than by CM(ECFCs) and CM(MSCs) separately (Supplementary Fig. 8). 
However, plugs containing CM from A-Grafts had no detectable neutrophils, a decline that 
occurred progressively and coincided with the assembly of cells into vascular networks (Fig. 
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5c). Moreover, human cells retrieved from A-Grafts could immediately regain ability to 
recruit neutrophils when used in new U-Grafts (Supplementary Fig. 8). Thus, neutrophil 
recruitment was mediated by secreted factors and was directly related to the state of the 
vascular cells (assembled vs. unassembled) within the grafts.
Next, we studied whether exposing A-Grafts to CM from U-Grafts could thus enhance 
engraftment of assembled bioengineered vessels (Fig. 5d). First, we observed that A-Grafts 
that were simply impregnated once with CM(U-Graft) at the time of implantation contained 
significantly more neutrophils at day 2 than the control (Fig. 5e). In addition, A-Grafts + 
CM(U-Graft) contained an extensive network of perfused microvessels at day 7 (Fig. 5f,g). 
Moreover, the extent to which CM(U-Grafts) induced revascularization of A-Grafts was 
significantly higher than that of CM(ECFCs) and CM(MSCs) separately (Supplementary 
Fig. 9). Examination of human-specific (h-CD31+) lumens revealed that A-Grafts + CM(U-
Graft) comprised perfused human microvessels that carried murine erythrocytes, indicating 
successful connection of pre-assembled vessels with the host circulatory system (Fig. 5h). In 
contrast, A-Grafts + basal-M had a significantly lower number of perfused human lumens at 
day 7 (8.7 ± 0.6 vessels/mm2 vs. 31.2 ± 7.0 vessels/mm2 in A-Grafts + CM(U-Graft)) (Fig. 
5i). Instead, human ECFCs remained organized as non-perfused cellular cords (Fig. 5f,h). 
Thus, a critical difference between U-Grafts and A-Grafts resides in the presence or absence 
of secreted factors that recruit and activate host neutrophils, which in turn modulate graft 
vascularization. Importantly, exogenous provision of factors from U-Grafts could reengage 
neutrophils and enhance revascularization in A-Grafts.
Inhibition of Notch signaling promotes revascularization
Microvascular stability is associated with activation of Notch in the endothelium 32,33. 
However, the relation between endothelial Notch signaling and neutrophil activity in the 
context of grafting remains largely unexplored. mRNA expression of NOTCH1, as well as 
several downstream mediators of Notch signaling (HEY1, HEY2, HES1, and HES5), was 
upregulated in ECFCs from A-Grafts compared to U-Grafts (Fig. 6a). Moreover, expression 
of human-specific genes (NOTCH1, HEY1, HEY2, and HES1) were all significantly up-
regulated by the human cells in implanted U-Grafts over a 7-day period, confirming the 
association between vascular maturity and Notch expression in vivo (Fig. 6a). Inversely, 
expression levels of several cytokines with neutrophil chemoattractant activity (namely, 
CXCL1, CXCL8, and IL6) were downregulated in ECFCs from A-Grafts (Fig. 6b), which 
coincided with reduced neutrophil presence. Cytokine analyses of CM confirmed 
widespread downregulation of numerous neutrophil chemoattractants in A-Grafts vs. U-
Grafts (Fig. 6c). Of note, exposing A-Grafts to the Notch inhibitor DAPT (a γ-secretase 
inhibitor) for 24 h reactivated the expression of several cytokines (most significantly 
CXCL1, CXCL8, and IL6) (Fig. 6c), suggesting a relationship between Notch activation and 
the secretion of neutrophil chemoattractants by the vasculature. Moreover, the use of 
antibodies to specifically block each of the identified cytokines (most significantly IL6 and 
CXCL8) in CM from U-Grafts interfered with the recruitment of neutrophils into 
subcutaneous plugs (Fig. 6d), whereas plugs containing CM from DAPT-treated A-Grafts 
recruited significantly more neutrophils than plugs with CM from untreated A-Grafts (Fig. 
6d).
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To further elucidate the significance of secreted cytokines, we examined the effect of a non-
peptide CXCR2 antagonist (SB225002) on the vascularization of U-Grafts. CXCR2 is a 
receptor for both CXCL8 and CXCL1, and previous studies have shown that SB225002 
effectively inhibits neutrophil chemotaxis in response to CXCL8 both in vitro and in vivo 34. 
Indeed, SB225002 treatment significantly impaired neutrophil presence in our implanted U-
Grafts at day 2 (Fig.6e). Importantly, U-Grafts that were implanted into SB225002-treated 
mice had significantly lower microvessel densities than those implanted into control animals 
(Fig.6f). To put this result in context, SB225002-treatment produced a reduction in 
vascularity that was similar to the reduction produced by depletion of host neutrophils with 
α-Ly6G antibody (Fig. 6f). Moreover, a combination treatment with α-Ly6G + SB225002 
further reduced microvessel density in U-Grafts (down to ~8 vessels/mm2), although the 
differences in reduction between the combination and each individual treatment were not 
statistically significant. Nevertheless, this additional reduction in microvessel density due to 
the combination treatment might suggest participation of an additional type of host CXCR2+ 
cells that, together with neutrophils, mediate graft vascularization.
Next, we examined whether deactivation of Notch could rescue the inherent lack of 
revascularization in A-Grafts. To this end, we incubated A-Grafts with DAPT for 24 h ahead 
of their implantation into mice. Compared to untreated grafts, DAPT-treated A-Grafts had 
significantly more neutrophils at day 2 (Fig. 6g). In addition, DAPT-treated A-Grafts 
contained more extensive networks of perfused microvessels that were unequivocally human 
after 7 days in vivo (Fig. 6h–j), and the difference in microvascular density between DAPT-
treated and untreated grafts was significant (Fig. 6k). Importantly, human vessels in DAPT-
treated A-Grafts were surrounded by perivascular α-SMA+ cells (Supplementary Fig. 10), 
indicating that the transient inhibition of Notch signaling did not compromise proper 
perivascular coverage.
DISCUSSION
In this study, we sought to determine the cellular mechanisms impairing engraftment of 
bioengineered human vascular networks. We showed that the inefficient formation of 
anastomoses in assembled microvessels (A-Grafts) is due to an inherent inability of mature 
vessels to engage a subset of alternatively polarized (non-inflammatory) host neutrophils at 
the implantation site. This contrasted with grafts comprising a non-assembled suspension of 
vascular cells (U-Grafts), which rapidly engage neutrophils to mediate proper 
vascularization. Depletion of host neutrophils significantly abrogated vasculogenesis in U-
Grafts, whereas an adoptive transfer of neutrophils restored vascularization in myeloid-
depleted mice. The dependency on host neutrophils was complete and corroborated in both 
syngeneic (murine grafts implanted into mouse) and xenograft (human in mouse) models. 
Neutrophil recruitment and activation were controlled by factors secreted from the implanted 
vascular cells, a process initially upregulated in unassembled U-Grafts but progressively 
silenced as the vasculature matured. This mechanism of progressive neutrophil 
disengagement could explain the inactive nature of assembled microvasculatures - both 
bioengineered and primary - with regards to their capacity to engraft and connect with host 
vessels.
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Emerging evidence indicate that neutrophils can comprise two distinct subpopulations with 
different polarized phenotypes: 1) a canonical pro-inflammatory phenotype (referred to as 
“N1”); and 2) an alternative anti-inflammatory, pro-remodeling, phenotype (“N2”) 31,35,36, 
resembling the well-established “M1–M2” macrophage paradigm. N2 polarization has been 
substantiated in a variety of tumor models, and it involves TGFβ-mediated activation (TGFβ 
inhibition produces a shift to N1, and in turn acquisition of antitumor activity), followed by 
downregulation of pro-inflammatory genes and expression of both anti-inflammatory factors 
and proangiogenic mediators 31,37,38. Recently, the contribution of alternatively polarized 
N2 neutrophils has also been described in non-neoplastic events, including brain stroke 39 
and myocardial infarction 40. However, their participation in tissue grafting was not 
previously described. Here, we identified that graft neutrophils displayed a phenotype that 
was consistent with the notion of an alternative N2 polarization in several respects including 
low expression of canonical pro-inflammatory genes, high expression of anti-inflammatory 
and pro-remodeling genes, low phagocytic activity, and TGFβR2-mediated activation. We 
also found that adoptive transfer of neutrophils from bone marrow restored vascularization 
in myeloid-depleted mice to a better extent than blood neutrophils, which is consistent with 
published evidence of immature non-inflammatory neutrophils (equivalent to “N2” 
neutrophils) being more abundant in the bone marrow than in circulation 37.
Though our study focused on the role of neutrophils in graft vascularization, our implants 
also contained host macrophages and monocytes. Macrophage presence was expected in 
light of their role as cellular chaperones for vascular anastomosis during angiogenesis 41. 
Furthermore, macrophage-neutrophil interdependency during angiogenesis is well 
established 42–44. In our studies, the indispensable role of neutrophils in graft vascularization 
did not preclude participation of host macrophages, which were also abundant at the onset of 
perfusion. However, we demonstrated that in the absence of neutrophils, macrophage 
involvement in vascularization was undoubtedly insufficient. With regard to host monocytes, 
our results were equally conclusive: depletion of circulating monocytes had no appreciable 
effect on graft vascularization and adoptive transfer of BM-derived F4/80+ cells could not 
restore normal vascular activity in myeloid-depleted mice. Lastly, our results with α-Ly6G 
(neutrophil depletion) + SB225002 (CXCR2 inhibitor) revealed that this combination 
reduced vascularization in U-Grafts more than either of the treatments separately, although 
the differences were not statistically significant. Nevertheless, the additional reduction in 
microvessel density with the combination treatment might indicate participation of an 
additional type of host CXCR2+ cells in vascularization, suggesting that neutrophils are 
likely not solely responsible for the vascularization of the grafts. Further research is 
warranted to confirm a role and to elucidate the nature of additional host CXCR2+ cells that 
may contribute to the process of graft vascularization.
Prior to our study, the mechanisms regulating engraftment of bioengineered microvessels 
remained essentially unexplored. Nevertheless, some recent studies did report positive 
integration between engineered and host vessels. Baranski and colleagues bioengineered 
vascular networks by the assembly of human ECs (HUVECs) and murine embryonic 
perivascular cells (10T1/2 cell line), and demonstrated perfusion with host blood upon 
implantation into the intraperitoneum of nude mice 45. More recently, Riemenschneider et. 
al. constructed patches containing self-assembled microvessels formed by co-entrapment of 
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ECFCs and human fetal brain pericytes in fibrin gel. These patches were sutured onto the 
epicardial surface of the hearts of athymic rats following permanent ligation of the left 
anterior descending artery; ~25% of the bioengineered vessels were found perfused 46. Thus, 
the poor engraftment seen with our bioengineered vessels might seem inconsistent with 
these previous reports. However, it is important to note that the sources of perivascular cells 
in the aforementioned studies were embryonic and fetal tissues, respectively. Considering 
that xenograft studies have shown that embryonic (but not adult) vasculature can form 
spontaneous connections with the host 47, it is conceivable that the sole presence of fetal 
cells could facilitate the formation of anastomoses. In any case, bioengineering tissues with 
non-autologous fetal cells poses additional challenges related to immune tolerance and thus 
may have reduced translational potential. Further studies are warranted to elucidate if host 
neutrophils also mediate vascular anastomoses in bioengineered vessels that use embryonic/
fetal cells.
Harnessing the pro-vascularization potential of neutrophils could become the basis for a new 
strategy to engraft bioengineered tissues. Moreover, this approach could potentially benefit 
grafting clinical procedures that critically rely on adequate revascularization. Clinical and 
preclinical studies have repeatedly shown that perfused vessels in adult primary tissue grafts 
are almost exclusively originated by infiltration of host vessels. However, this process of 
revascularization poses two main constraints on the grafts: (1) inadequate blood supply to 
the center, which leads to necrosis and resorption; and (2) irreversible loss of graft 
endogenous vasculature. The latter is important because mounting evidence indicates that 
most tissues have highly specialized endothelium that regulates homeostatic and 
regenerative processes in a tissue-specific manner 48–52. Thus, loss of endogenous vessels 
could contribute to long-term malfunctioning of the grafts. Enabling a robust integration of 
the graft microvasculature could eliminate the abovementioned constraints. In light of our 
study, new strategies to improve microvascular engraftment could focus on harnessing non-
inflammatory neutrophils by exposing the grafts to specific exogenous vascular factors 
and/or blocking Notch signaling, which could reactivate endogenous mechanisms in mature 
vessels. We anticipate that forthcoming studies will address whether engaging host 
neutrophils would indeed improve revascularization of primary tissue grafts and how this 
strategy would ultimately affect parenchymal function in the engrafted tissues.
METHODS
Mice
Nu/nu (BALB/c background; Massachusetts General Hospital) and C57BL/6 males (Jackson 
Laboratory) were used for implantation of human and syngeneic murine grafts, respectively, 
unless stated otherwise. Rosa26fsTrap (129S1 background) and Cdh5(Pac)-CreERT2+ 
(C57BL/6 background) transgenic mice 53,54 were interbred and offspring were given two 
consecutive intragastric injections of 50 μl tamoxifen (2 mg/ml in sunflower seed oil) on 
postnatal day P1 and P2 to induce Cre recombinase activity. The resulting 
Rosa26fsTrap;Cdh5(Pac)-CreERT2+ mice served as donors and their tissues expressed eGFP-
L10a fusion protein in endothelial cells. For myeloid-specific tgfbr2 deletions, LysM-Cre 
transgenic mice (Jackson Laboratory, JAX004781) were interbred with conditional 
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Tgfbr2lox/lox mutants (JAX012603; both C57BL/6 background). The offspring were 
interbred again and genotyped to select homozygous tgfbr2−/− (LysM-Cre+/+ Tgfbr2lox/lox) 
alleles. The myeloid-specific deletions of tgfbr2 were confirmed by PCR. Animal 
experiments were conducted under a protocol approved by the Institutional Animal Care and 
Use Committee at Children’s Hospital Boston in an AAALAC-approved facility.
Transplantation of primary murine tissue grafts
6-weeks-old Rosa26fsTrap;Cdh5(Pac)-CreERT2+ transgenic mice served as donors and were 
perfused with PBS before being euthanized. Myocardium, liver and kidney were harvested 
and trimmed into 3x3x3 mm3 grafts. Tissue grafts were then surgically implanted into 
subcutaneous space on the back of nude mice with 50-μL of collagen-fibrin gel (3 mg/mL of 
bovine collagen, 30 μg/mL of human fibronectin, 25mM HEPES, 10% 10x DMEM, 10% 
FBS, and 3 mg/mL of fibrinogen, pH neutral; mixed with 10 μL of 10 U/mL thrombin 
immediately before implantation). After 7 days in vivo, fluorescein isothiocyanate (FITC)-
conjugated Griffonia Simplicifolia Lectin I (GSL I) isolectin B4 in saline (Iso-B4; 50 μg/100 
μL/mouse) was infused intravenously 10 min before euthanasia. Grafts were explanted and 
subjected to histological analyses. Anti-FITC and anti-GFP antibodies were used to stain 
perfused and donor vessels, respectively.
Transplantation of primary human myocardial tissue grafts
Discarded normal human right ventricular myocardial tissues were obtained during 
clinically-indicated procedures in accordance with an Institutional Review Board-approved 
protocol. Myocardial tissues were immediately transported to the laboratory in cold sterile 
saline, trimmed into 3x3x3 mm3 cubes, and surgically implanted (subcutaneously) into nude 
mice. 50-μL of collagen-fibrin gel was added around myocardial grafts to improve 
integration with host tissues. 7 days after implantation, FITC-conjugated Ulex Europaeus 
Agglutinin-I in saline (UEA-I; 50 μg/100 μL/mouse) was infused intravenously 10 min 
before euthanasia. Grafts were explanted and subjected to histological analyses. Perfused 
human vessels were stained by biotinylated-anti UEA-I antibody and streptavidin-TexasRed.
Isolation and culture of human MSCs and ECFCs
Human MSCs were isolated from the mononuclear cell fraction of bone marrow aspirates as 
previously described 7. MSCs were cultured on uncoated plates using MSC-medium: 
MSCGM (Lonza) supplemented with 10% MSC-qualified FBS (Hyclone), 1x glutamine-
penicillin-streptomycin (GPS; Invitrogen). All experiments were carried out with MSCs 
between passages 6–10. Human ECFCs were isolated from umbilical cord blood samples in 
accordance with an Institutional Review Board-approved protocol as previously 
described 27. ECFCs were cultured on 1% gelatin-coated plates using ECFC-medium: 
EGM-2 (except for hydrocortisone; Lonza) supplemented with 20% FBS, 1x GPS. All 
experiments were carried out with ECFCs between passages 6–8. DsRed-labeled ECFCs 
were generated by lentiviral infection with a pLVX-DsRed vector (Clontech) and selected 
with puromycin (2 μg/mL) 5.
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Fabrication and implantation of bioengineered grafts
Photopolymerizable methacrylated gelatin (GelMA) hydrogel was synthesized as previously 
described 5. GelMA prepolymer solution was prepared in PBS at 80°C (5 w/v% final) with 
photoinitiator Irgacure 2959 (0.5 w/v%; CIBA Chemicals), and then allowed to cool down to 
37°C in a water bath. ECFCs and MSCs (4x105 total; 1:1 ratio) were suspended in 200 μL of 
GelMA solution and the mixture was polymerized by exposure to 7.5 mW/cm2 UV light for 
15 s at 37°C. Polymerized cell-laden constructs were referred to as unassembled grafts or U-
Grafts. Alternatively, on indicated experiments, U-Grafts were constructed with ice-cold 
Phenol Red-free Matrigel (BD Bioscience). Assembled grafts or A-Grafts were constructed 
by culturing U-Grafts in vitro for 7 days using EGM-2 with 5% FBS. A-Grafts contained 
easily observable, fully-assembled vascular networks. Both, U-Grafts and A-Grafts were 
subcutaneously implanted into back of 6-week-old male athymic nu/nu mice for engraftment 
studies. On specified experiments, DsRed-labeled ECFCs were used to visualize the 
formation of assembled vascular networks in A-Grafts. For Notch signaling inhibition 
studies, A-Grafts were treated with the γ-secretase inhibitor DATP (10 μM in EGM-2 with 
5% FBS) for 24 h prior to implantation; A-Grafts cultured for 8 days in EGM-2 with 5% 
FBS served as a control. To evaluate host myeloid cell recruitment, grafts were explanted 
two days after implantation and subjected to flow cytometric and histological analyses. To 
assess vascularization, grafts were explanted 7 days after implantation and were subjected to 
histological analysis. On indicated experiments, FITC-conjugated UEA-I (50 μg/100 μL per 
mouse) was injected intravenously 10 min before euthanasia to label perfused human 
vessels.
Isolation and culture of murine MSCs and ECs
Subcutaneous white fat pads were excised from euthanized C57BL/6 mice, minced, and 
digested (1 mg/mL collagenase A, 2.5 U/mL dispase, 126 μM calcium chloride, and 80 μM 
magnesium sulfate in DMEM containing 1% FBS) for 1 hr at 37°C. The stromal vascular 
fractions (SVFs) were obtained after removal of mature adipocytes by centrifugation (450 g 
for 10 min) and the lysis of erythrocytes with ammonium chloride solution. The SVFs were 
incubated with a FITC-conjugated anti-mouse CD45 antibody, followed by anti-FITC 
magnetic microbeads (Miltenyi Biotec), and passed through magnetic columns (Miltenyi 
Biotec). The mCD45- cell fraction was then incubated with a PE-conjugated anti-mPDGFR-
β or anti-mCD31 antibodies, followed by anti-PE magnetic microbeads, and passed through 
magnetic columns. The purified mCD45-/mPDGFR-β+ murine MSCs (mMSCs) were 
cultured on uncoated tissue culture dishes using MSC-medium. The purified mCD45-/
mCD31+ ECs (mECs) were cultured on fibronectin-coated tissue culture dishes using 
ECFC-medium. mECs were then transduced with lentivirus (pLenti-CMV-GFP; Addgene) 
to express GFP under CMV promoter (referred to as GFP-mECs). All experiments were 
carried out with mMSCs at passage 3 and GFP-mECs at passage 12.
Syngeneic murine model of graft vascularization
C57BL/6-derived mMSCs and GFP-mECs were implanted in collagen-fibrin gel (2x106 
total; 3:2 ratio; 200 μL) subcutaneously into host C57BL/6 males as U-Grafts in a syngeneic 
murine model. To evaluate host myeloid cell recruitment, grafts were explanted two days 
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after implantation and subjected to flow cytometric analyses. To assess vascularization, 
grafts were explanted 7 days after implantation and were subjected to histological analysis. 
Immunofluorescent staining of GFP indicated the grafting of donor GFP-mECs.
Histology and immunohistochemistry
Explanted grafts were fixed overnight in 10% buffered formalin, embedded in paraffin and 
sectioned (7-μm-thick). Hematoxylin and eosin (H&E)-stained sections were examined for 
the presence of erythrocyte-filled blood vessels. For immunostaining, sections were 
deparaffinized and antigen retrieval was carried out with tris-EDTA buffer (10 mM Tris-
Base, 2 mM EDTA, 0.05% Tween-20, pH 9.0) or citric buffer (10 mM sodium citrate, 0.05% 
Tween 20, pH 6.0). Sections were then blocked for 30 min in 5–10% blocking serum and 
incubated with primary antibodies overnight at 4°C. Horseradish peroxidase-conjugated 
mouse secondary antibody (1:200; Vector Laboratories) and 3,3′-diaminobenzidine (DAB) 
were used for detection of h-CD31, followed by hematoxylin counterstaining and Permount 
mounting. Fluorescent staining was performed using fluorescently-conjugated secondary 
antibodies (1:200) followed by DAPI counterstaining (Vector Laboratories). When indicated, 
h-vimentin staining was used to identify human cells (both ECFCs and MSCs) (please note 
that the anti-h-vimentin antibody used is very specific to human vimentin and does not react 
with murine cells and tissues) 7. Primary and secondary antibodies are detailed in 
Supplementary Table 1.
Microvessels density
Microvessel density was reported as the average number of erythrocyte-filled vessels 
(vessels/mm2) in H&E-stained sections from the middle of the implants as previously 
described 7. The entire area of each section was analyzed. On specified experiments, human-
specific microvessel density was quantified by evaluation of slides immunostained for 
human-specific CD31 (h-CD31). Perfused microvessel density was measured by injection of 
FITC-labeled lectins (UEA-1 or Iso-B4) before euthanizing graft-bearing mice, followed by 
staining of lectin-labeled vessels with anti-UEA-1 or anti-FITC antibodies.
Cell retrieval and flow cytometry
Grafts were removed from euthanized mice and cells were retrieved by enzymatic (1 mg/mL 
collagenase and 2.5 U/mL dispase) digestion for 1 h at 37 °C. Retrieved cells were then 
prepared into single-cell suspensions. In indicated experiments, retrieved cells were sorted 
into h-CD31+ and h-CD31− cells by magnetic-activated cell sorting (MACS) using 
magnetic beads (DynaBead) coated with anti-human CD31 antibodies. Retrieved cells were 
also stained for flow cytometry and analyzed using a Guava easyCyte 6HT/2L flow 
cytometer (Millipore Corporation, Billerica, MA) and FlowJo software (Tree Star Inc., 
Ashland, OR). Antibody labeling was carried out for 20 min on ice followed by 3 washes 
with PBS supplemented with 1% BSA and 0.2 mM EDTA. Cell staining was followed by 
fixation with 1% paraformaldehyde. To identify murine myeloid population, cell 
suspensions were incubated with PerCP-conjugated anti-mouse CD45, PE-conjugated anti-
mouse F4/80 and FITC-conjugated anti-mouse Ly6G with concentrations indicated in 
Supplementary Table 1. Murine neutrophils were identified as mCD45+/mLy6G+ cells. 
Murine monocytes and macrophages were identified as mCD45+/mLy6G-/mF4/80dim cells 
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and mCD45+/mLy6G-/mF4/80high cells, respectively. To identify murine lymphocytes, cell 
suspensions were incubated with PerCP-conjugated anti-mouse CD45, PE-conjugated anti-
mouse CD19 and FITC-conjugated anti-mouse CD3e. Murine T cells and B cells were 
identified as mCD45+/mCD3+ and mCD45+/mCD19+ cells, respectively. In indicated 
experiments, retrieved cells were sorted into mCD45+/mLy6G+ (neutrophils) and mCD45+/
mLy6G- cells by fluorescence-activated cell sorting (FACS) using a FACSAria II 5-LASER 
sorter system (BD Bioscience). Sorted cells were analyzed immediately for gene expression 
by qPCR.
Myeloid cell depletion
Antibodies were administered intraperitoneally according to the schedule described in Fig. 
2a. Rat anti-mouse Ly-6G (clone 1A8; Bio X Cell) antibodies were administered at 200 μg/
mouse 2 days before U-grafts implantation, and then every other day at 100 μg/mouse. Rat 
anti-mouse F4/80 (clone CI:A3-1; Bio X Cell) antibodies were administered at 400 μg/
mouse 2 days before U-grafts implantation, and then every day at 200 μg/mouse. Daily 
injection of rat IgG (200 μg/mouse) served as control. Monocyte and neutrophil depletion 
was confirmed in blood samples by flow cytometry.
Myeloid adoptive transfer model
Circulating myeloid cells were depleted from recipient mice by two 4Gy gamma irradiation 
sessions at days −4 and 0. mLy6G+ neutrophils or mF4/80+ cells (~107 cells) from non-
irradiated donor mice were adoptively transferred by injection at the implantation sites in 
recipient mice and at the same time of U-Graft implantation (day 0). Donor neutrophils were 
isolated from either bone marrow or blood using a murine neutrophil isolation kit that 
enriches for CD11b+/Ly6G+ cells (Miltenyi Biotec; negative selection using a cocktail that 
contains anti CD5, CD45R/B220, CD49b, CD117/c-kit, F4/80 and Ter119 antibodies). 
Donor mF4/80+ cells were isolated from bone marrow by magnetic-activated cell sorting 
(MACS) using magnetic beads (Miltenyi Biotec) coated with anti-mF4/80 antibodies.
Generation of conditioned media
Samples of conditioned media (CM) were collected daily from U-Grafts over 8 days in vitro 
(i.e., until they became A-Grafts). To this end, grafts were cultured in 3-mL tubes with 500 
μL of EBM-2, 5% FBS media refreshed every 24 h. Collected CM samples were filtered (0.2 
μm) and then concentrated 10-fold (Amicon Ultra centrifugal filters; 3 kDa cut off; 
Millipore). In indicated experiments, A-Grafts were impregnated with CM from U-Grafts. 
To this end, A-Grafts were placed on clean kimwipes (2x2 cm2) and then concentrated CM 
(50 μL) from U-Grafts was added on top of the grafts slowly to allow a replacement of 
culture medium by capillary force. Impregnated A-Grafts were immediately implanted into 
recipient mice. A-Grafts impregnated in basal media (basal-M: EBM-2, 5% FBS) and CM 
from grafts containing only ECFCs or MSC alone served as controls.
Neutrophil recruitment plug assay
Concentrated CM (50 μL) was mixed with 200-μL of Matrigel and injected subcutaneously 
into nu/nu mice. After 2 days, plugs were explanted and infiltrated cells were retrieved by 
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enzymatic digestion and subjected to flow cytometric analysis. Concentrated basal media 
(basal-M: EBM-2, 5% FBS) served as control. In indicated experiments, neutralizing 
antibodies against IL6, CXCL1 or CXCL8 (5 μg/antibody/plug) were added to concentrated 
CM 30 min prior to implantation. Individual neutralizing antibodies and the combination of 
three were compared.
CXCR2 antagonist treatment
CXCR2 antagonist SB225002 (Sigma) was administered at 7.5 mg/kg intraperitoneally 30 
mins before U-grafts implantation, and then every day until day 7. Neutrophil recruitment at 
day 2 and graft vascularization at day 7 were measured as described before. Daily injection 
of saline served as control. In selected experiments, SB225002 treatment was combined with 
rat anti-mouse Ly-6G treatment (clone 1A8; administered as described above) to study the 
combined effect on U-Graft vascularization.
TGF-β receptor inhibitor treatment
U-Grafts were implanted in mice systemically treated with a TGF-β receptor inhibitor 
(SB432542; 10 mg/kg of animal weight; daily intraperitoneal injection). Mice receiving 
saline injections served as controls. Grafts were harvested at day 7 to evaluate 
vascularization.
LPS plug assay
Lipopolysaccharides (LPS; 10 μg; from E. coli 0111:B4; Sigma) were mixed with 200-μL 
Matrigel and was injected subcutaneously into nu/nu mice. After 1 day, plugs were 
explanted, infiltrated cells were retrieved, and neutrophils were sorted by FACS for analysis.
Phagocytosis assay
Cells were retrieved from U-Grafts or LPS plugs 24 h after implantation and were then 
incubated with GFP-expressing E. coli. for 30 min. Cells were washed twice in PBS and free 
bacteria were removed by centrifugation (300 rpm). Cells were analyzed by flow cytometry 
and immunofluorescence. Murine neutrophils were identified as mCD45+/mLy6G+ cells 
and phagocyted E. coli as GFP+ bacteria.
Human cytokine protein array
The presence of selected cytokines was evaluated in samples of CM with human cytokine 
protein arrays (R&D Systems Inc.) according to the manufacturer’s instructions. Antigen-
antibody complexes were visualized using LumiGLO substrate (Kirkegaard & Perry 
Laboratories, Inc.) and chemiluminescent sensitive film (Kodak). Densitometry was 
performed by image analysis (ImageJ) to estimate the amount of protein present in each 
sample.
Quantitative RT-PCR
Quantitative RT-PCR (qRT-PCR) was carried out in RNA lysates prepared from either 
explanted grafts, cells in culture, or cells retrieved from grafts. Total RNA was isolated with 
a RNeasy kit (QIAGEN) and cDNA was prepared using reverse transcriptase III 
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(Invitrogen), according to the manufacturer’s instructions. Multigene transcriptional 
profiling, a form of qRT-PCR, was used to determine the number of mRNA copies per cell 
normalized to ribosomal 18S rRNA abundance, as previously described 55. Human-specific 
gene expression in explanted grafts were measured using human-specific primers and 
normalized to human beta actin (ACTB) expression. Real-time PCR primer sequences are 
displayed in Supplementary Table 2. Heat maps were generated using Gene-E software 
package from the Broad Institute (www.broadinstitute.org/cancer/software/GENE-E/).
Microscopy
Images were taken using an Axio Observer Z1 inverted microscope (Carl Zeiss) and 
AxioVision Rel. 4.8 software. Fluorescent images were taken with an ApoTome.2 Optical 
sectioning system (Carl Zeiss) and 20x/0.8 or 40x/1.4 oil objective lens. Non-fluorescent 
images were taken with an AxioCam MRc5 camera using a 40x/1.4 objective oil lens.
Statistical analyses
Unless otherwise stated, data were expressed as mean ± standard deviation of the mean 
(s.d.). For comparisons between two groups, means were compared using unpaired two-
tailed Student’s t-tests. Comparisons between multiple groups were performed by ANOVA 
followed by Bonferroni’s post-test analysis. Samples size, including number of mice per 
group, was chosen to ensure adequate power and were based on historical data. No exclusion 
criteria was applied for all analyses. No specific methods of randomization were applied to 
group/animal allocation. Investigators were not blinded to group allocation. All statistical 
analyses were performed using GraphPad Prism v.5 software (GraphPad Software Inc.). 
P<0.05 was considered statistically significant.
Data availability
The authors declare that all data supporting the findings of this study are available in the 
paper and its Supplementary Information.
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Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank Dr. Shou-Ching S. Jaminet and Dan Li (Center for Vascular Biology, Beth Israel Deaconess Medical 
Center, Boston) for quantitative reverse transcription-polymerase chain reaction analyses. Histology was supported 
by Core Facility of the Dana-Farber/Harvard Cancer Center (P30 CA06516). This work was supported by National 
Institutes of Health grants R00EB009096, R01AR069038, R01HL128452, and R21AI123883 to J. M.-M.
References
1. Griffith LG, Naughton G. Tissue Engineering--Current Challenges and Expanding Opportunities. 
Science. 2002; 295:1009–1014. [PubMed: 11834815] 
2. Rouwkema J, Rivron NC, Van Blitterswijk CA. Vascularization in tissue engineering. Trends 
Biotechnol. 2008; 26:434–441. [PubMed: 18585808] 
3. Novosel EC, Kleinhans C, Kluger PJ. Vascularization is the key challenge in tissue engineering. Adv 
Drug Deliv Rev. 2011; 63:300–311. [PubMed: 21396416] 
Lin et al. Page 15
Nat Biomed Eng. Author manuscript; available in PMC 2017 December 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4. Schechner JS, et al. In vivo formation of complex microvessels lined by human endothelial cells in 
an immunodeficient mouse. Proc Natl Acad Sci USA. 2000; 97:9191–9196. [PubMed: 10890921] 
5. Chen YC, et al. Functional Human Vascular Network Generated in Photocrosslinkable Gelatin 
Methacrylate Hydrogels. Adv Funct Mater. 2012; 22:2027–2039. [PubMed: 22907987] 
6. Jain RK, Au P, Tam J, Duda DG, Fukumura D. Engineering vascularized tissue. Nat Biotechnol. 
2005; 23:821–823. [PubMed: 16003365] 
7. Melero-Martin JM, et al. Engineering robust and functional vascular networks in vivo with human 
adult and cord blood-derived progenitor cells. Circ Res. 2008; 103:194–202. [PubMed: 18556575] 
8. Traktuev DO, et al. Robust functional vascular network formation in vivo by cooperation of adipose 
progenitor and endothelial cells. Circ Res. 2009; 104:1410–1420. [PubMed: 19443841] 
9. Chen X, et al. Rapid anastomosis of endothelial progenitor cell-derived vessels with host vasculature 
is promoted by a high density of cotransplanted fibroblasts. Tissue Eng Part A. 2010; 16:585–594. 
[PubMed: 19737050] 
10. Moisidis E, Heath T, Boorer C, Ho K, Deva AK. A Prospective, Blinded, Randomized, Controlled 
Clinical Trial of Topical Negative Pressure Use in Skin Grafting. Plast Reconstr Surg. 2004; 
114:917–922. [PubMed: 15468399] 
11. Larry MW, Eber LLS. Considerations in nerve repair. Proceedings (Baylor University Medical 
Center). 2003; 16:152–156. [PubMed: 16278731] 
12. Giannoudis PV, Dinopoulos H, Tsiridis E. Bone substitutes: An update. Injury. 2005; 36:S20–S27. 
[PubMed: 16188545] 
13. Kølle S, Fischer-Nielsen A, Mathiasen AB, Elberg JJ. Enrichment of autologous fat grafts with ex-
vivo expanded adipose tissue-derived stem cells for graft survival: a randomised placebo-
controlled trial. Lancet. 2013; 13:1113–1120.
14. Mohr FW, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in 
patients with three-vessel disease and left main coronary disease: 5-year follow-up of the 
randomised, clinical SYNTAX trial. Lancet. 2013; 381:629–638. [PubMed: 23439102] 
15. Serruys PW, et al. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting 
for Severe Coronary Artery Disease. N Engl J Med. 2009; 360:961–972. [PubMed: 19228612] 
16. Rogers GF, Greene AK. Autogenous bone graft: basic science and clinical implications. J 
Craniofac Surg. 2012; 23:323–327. [PubMed: 22337435] 
17. Nahrendorf M, et al. The healing myocardium sequentially mobilizes two monocyte subsets with 
divergent and complementary functions. J Exp Med. 2007; 204:3037–3047. [PubMed: 18025128] 
18. Grunewald M, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of 
accessory cells. Cell. 2006; 124:175–189. [PubMed: 16413490] 
19. Shojaei F, Zhong C, Wu X, Yu L, Ferrara N. Role of myeloid cells in tumor angiogenesis and 
growth. Trends Cell Biol. 2008; 18:372–378. [PubMed: 18614368] 
20. De Palma M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required 
for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 
2005; 8:211–226. [PubMed: 16169466] 
21. De Palma M, Venneri MA, Roca C, Naldini L. Targeting exogenous genes to tumor angiogenesis 
by transplantation of genetically modified hematopoietic stem cells. Nat Med. 2003; 9:789–795. 
[PubMed: 12740570] 
22. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a 
mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA. 2006; 103:12493–12498. 
[PubMed: 16891410] 
23. Bekes EM, et al. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate 
coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J 
Pathol. 2011; 179:1455–1470. [PubMed: 21741942] 
24. Piccard H, Muschel RJ, Opdenakker G. On the dual roles and polarized phenotypes of neutrophils 
in tumor development and progression. Crit Rev Oncol Hematol. 2012; 82:296–309. [PubMed: 
21798756] 
25. Christoffersson G, et al. VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset 
that induces angiogenesis in transplanted hypoxic tissue. Blood. 2012; 120:4653–4662. [PubMed: 
22966168] 
Lin et al. Page 16
Nat Biomed Eng. Author manuscript; available in PMC 2017 December 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
26. Massena S, et al. Identification and characterization of VEGF-A-responsive neutrophils expressing 
CD49d, VEGFR1, and CXCR4 in mice and humans. Blood. 2015; 126:2016–2026. [PubMed: 
26286848] 
27. Melero-Martin JM, et al. In vivo vasculogenic potential of human blood-derived endothelial 
progenitor cells. Blood. 2007; 109:4761–4768. [PubMed: 17327403] 
28. Lin RZ, Chen YC, Moreno-Luna R, Khademhosseini A, Melero-Martin JM. Transdermal 
regulation of vascular network bioengineering using a photopolymerizable methacrylated gelatin 
hydrogel. Biomaterials. 2013; 34:6785–6796. [PubMed: 23773819] 
29. Melero-Martin JM, et al. Host myeloid cells are necessary for creating bioengineered human 
vascular networks in vivo. Tissue Eng Part A. 2010; 16:2457–2466. [PubMed: 20218762] 
30. Lin RZ, et al. Human endothelial colony-forming cells serve as trophic mediators for mesenchymal 
stem cell engraftment via paracrine signaling. Proc Natl Acad Sci USA. 2014; 111:10137–10142. 
[PubMed: 24982174] 
31. Fridlender ZG, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” 
versus ‘N2’ TAN. Cancer Cell. 2009; 16:183–194. [PubMed: 19732719] 
32. Suchting S, et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation 
and vessel branching. Proc Natl Acad Sci USA. 2007; 104:3225–3230. [PubMed: 17296941] 
33. Roca C, Adams RH. Regulation of vascular morphogenesis by Notch signaling. Genes & 
Development. 2007; 21:2511–2524. [PubMed: 17938237] 
34. White JR, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits 
interleukin-8-induced neutrophil migration. J Biol Chem. 1998; 273:10095–10098. [PubMed: 
9553055] 
35. Mantovani A. The yin-yang of tumor-associated neutrophils. Cancer Cell. 2009; 16:173–174. 
[PubMed: 19732714] 
36. Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis. 2012; 
33:949–955. [PubMed: 22425643] 
37. Sagiv JY, et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in 
cancer. Cell Rep. 2015; 10:562–573. [PubMed: 25620698] 
38. Fridlender ZG, et al. Transcriptomic analysis comparing tumor-associated neutrophils with 
granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS ONE. 2012; 
7:e31524. [PubMed: 22348096] 
39. Cuartero MI, et al. N2 neutrophils, novel players in brain inflammation after stroke: modulation by 
the PPARγ agonist rosiglitazone. Stroke. 2013; 44:3498–3508. [PubMed: 24135932] 
40. Ma Y, et al. Temporal neutrophil polarization following myocardial infarction. Cardiovasc Res. 
2016; 110:51–61. [PubMed: 26825554] 
41. Fantin A, et al. Tissue macrophages act as cellular chaperones for vascular anastomosis 
downstream of VEGF-mediated endothelial tip cell induction. Blood. 2010; 116:829–840. 
[PubMed: 20404134] 
42. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into 
hypoxic areas of tumors and other ischemic tissues. Blood. 2004; 104:2224–2234. [PubMed: 
15231578] 
43. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of 
tumour angiogenesis. Nat Rev Cancer. 2008; 8:618–631. [PubMed: 18633355] 
44. Benelli R, et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of 
angiogenesis and inflammation. FASEB J. 2002; 16:267–269. [PubMed: 11772950] 
45. Baranski JD, et al. Geometric control of vascular networks to enhance engineered tissue integration 
and function. Proc Natl Acad Sci USA. 2013; 110:7586–7591. [PubMed: 23610423] 
46. Riemenschneider SB, et al. Inosculation and perfusion of pre-vascularized tissue patches 
containing aligned human microvessels after myocardial infarction. Biomaterials. 2016; 97:51–61. 
[PubMed: 27162074] 
47. Ausprunk DH, Knighton DR, Folkman MJ. Vascularization of normal and neoplastic tissues 
grafted to the chick chorioallantois. Role of host and preexisting graft blood vessels. Am J Pathol. 
1975; 79:597–618. [PubMed: 1094838] 
Lin et al. Page 17
Nat Biomed Eng. Author manuscript; available in PMC 2017 December 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
48. Nolan DJ, et al. Molecular signatures of tissue-specific microvascular endothelial cell 
heterogeneity in organ maintenance and regeneration. Dev Cell. 2013; 26:204–219. [PubMed: 
23871589] 
49. Lee JH, et al. Lung stem cell differentiation in mice directed by endothelial cells via a BMP4-
NFATc1-thrombospondin-1 axis. Cell. 2014; 156:440–455. [PubMed: 24485453] 
50. Hu J, et al. Endothelial cell-derived angiopoietin-2 controls liver regeneration as a spatiotemporal 
rheostat. Science. 2014; 343:416–419. [PubMed: 24458641] 
51. Kusumbe AP, Ramasamy SK, Adams RH. Coupling of angiogenesis and osteogenesis by a specific 
vessel subtype in bone. Nature. 2014; 507:323–328. [PubMed: 24646994] 
52. Shen Q, et al. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem 
cells. Science. 2004; 304:1338–1340. [PubMed: 15060285] 
53. Zhou P, et al. Interrogating translational efficiency and lineage-specific transcriptomes using 
ribosome affinity purification. Proc Natl Acad Sci USA. 2013; 110:15395–15400. [PubMed: 
24003143] 
54. Wang Y, et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature. 
2010; 465:483–486. [PubMed: 20445537] 
55. Lin RZ, et al. Induction of erythropoiesis using human vascular networks genetically engineered 
for controlled erythropoietin release. Blood. 2011; 118:5420–5428. [PubMed: 21937702] 
Lin et al. Page 18
Nat Biomed Eng. Author manuscript; available in PMC 2017 December 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Engraftment of bioengineered microvascular networks
(a) Schematic of microvascular graft models. Grafts were prepared in vitro by combining 
human ECFCs with MSCs in hydrogels and then surgically implanted into nude mice. 
Assembled vascular grafts (A-grafts) were created over 7 days in vitro, whereas 
unassembled grafts (U-grafts) contained a suspension of cells. (b) H&E staining of A-Grafts 
and U-Grafts explanted after 7 days in vivo. Insets are macroscopic views of the explants. 
Perfused vessels were identified as luminal structures containing red blood cells (RBCs) 
(yellow arrowheads). (c) Immunohistochemical staining of h-CD31+ cells at day 7. Human 
h-CD31+ vascular structures were identified as either perfused (lumens containing RBC) or 
non-perfused (cord structures). (d) Density of perfused human blood vessels at day 7. Bars 
represent mean ± s.d.; n = 3 mice per group. *** P < 0.001 between A-Grafts and U-Grafts. 
(e) Time-course cytometric quantification of myeloid cell subpopulations in U-Grafts. (f) 
Cytometric quantification of neutrophils (N) and macrophages (MΦ) in U-Grafts and A-
Grafts at day 2 post-implantation. Bars represent mean ± s.d.; n = 3 grafts per group. ** P < 
0.01, * P < 0.05 between A-Grafts and U-Grafts. Immunofluorescent staining of (g) Ly6G+ 
neutrophils (red) and (h) F4/80+ macrophages (red) in U-Grafts and A-Grafts at day 2 post-
implantation. Human cells visualized as h-vimentin+ cells (green). Nuclei stained by DAPI. 
Scale bars: 100 μm (b, c) and 50 μm (a, g, h).
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Figure 2. Host neutrophils are indispensable for graft vascularization
(a) Schematic with myeloid depletion strategies. Circulating monocytes depleted with α-
F4/80 antibodies (α-F4/80). Neutrophils depleted with α-Ly6G antibodies (α-Ly6G). U-
Graft implanted at day 0. Control (IgG antibodies) and treatments initiated at day −2 and 
maintained until day 7. (b) Flow cytometry analysis of blood samples 2 days after depletion 
treatments. Gates for circulating monocytes (Mo) and neutrophils (N) depicted. Bars 
represent mean ± s.d.; n = 3–4. *** P < 0.001, ** P < 0.01, * P < 0.05 compared to IgG 
group. (c) H&E staining of U-Grafts explanted at day 7. Insets are macroscopic views of the 
explants. Perfused vessels were identified as luminal structures containing RBCs (yellow 
arrowheads). (d) Density of perfused blood vessels at day 7. Bars represent mean ± s.d.; n = 
4–6 mice per group. *** P < 0.001 compared to IgG group. (e) Schematic with neutrophil 
adoptive transfer strategy. U-Graft implanted into irradiated mice and neutrophils 
simultaneously transferred from non-irradiated donors. (f) Macroscopic views of U-Grafts 
explanted at day 7 from: (i) non-irradiated mice, (ii) irradiated mice, (iii) irradiated mice + 
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transfer of BM-Ly6G+ cells, and (iv) irradiate mice + transfer of BM-F4/80+ cells. (g) H&E 
and (h) immunohistochemical (h-CD31+ cells) staining of U-Grafts explanted at day 7 from 
irradiated mice with and without BM-Ly6G+ cell transfer. Perfused vessels marked by 
yellow arrowheads. (i) Microvessel density at day 7. Bars represent mean ± s.d.; n = 3–4 
mice per group. *** P < 0.001, * P < 0.05 compared to irradiated group (no transfer). † P < 
0.001 compared to irradiated + BM-Ly6G+ cell transfer. § P < 0.05 compared to irradiated + 
Blood-Ly6G+ cell transfer. Scale bars: 100 μm (c, g, h).
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Figure 3. Host neutrophils are indispensable for graft vascularization in a syngeneic murine 
C57BL/6 model
(a) Schematic of syngeneic grafting model on C57BL/6 mice. Subcutaneous tissues from 
C57BL/6 mice were enzymatically digested into single cell suspension. Magnetic-activated 
cell sorting (MACS) was performed to purify mouse ECs (mECs; CD31+) and mouse MSCs 
(mMSCs; PDGFRβ+). mECs were lentivirally transduced to express GFP. GFP-mECs and 
mMSCs were then implanted as U-Grafts into host C57BL/6 mice. (b) Neutrophils were 
depleted with α-Ly6G antibodies in C57BL/6 mice. U-Graft containing GFP-mECs and 
mMSCs were implanted at day 0. Control (IgG antibody) and α-Ly6G treatments were 
initiated at day −2 and maintained until day 7. Lower panels show macroscopic views of the 
subcutaneous grafts at day 7. (c) H&E staining of U-Grafts explanted at day 7. Insets are 
macroscopic views of the explants. Perfused vessels were identified as luminal structures 
containing RBCs (yellow arrowheads). (d) Density of perfused blood vessels at day 7. Bars 
represent mean ± s.d.; n = 3 mice per group. *** P < 0.001 compared to control. (e) Vessels 
lined by donor mECs were identified by GFP and perivascular coverage by α-SMA+ 
staining. Nuclei stained by DAPI. (f) Flow cytometry analysis of murine U-Grafts implanted 
in C57BL/6 host. Cytometric analyses included blood samples and cells retrieved from 
explanted U-Grafts at day 2. B cells were identified as mCD19-positive cells and T cells as 
mCD3-positive. Scale bars: 4 mm (b) and 100 μm (c, e).
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Figure 4. Alternatively polarized neutrophils mediate U-Graft vascularization
(a) Schematic with neutrophils (N) isolated from either explanted U-Grafts or from 
lipopolysaccharide (LPS)-containing plugs. (b) Heat map of gene expression levels (by 
qPCR) in neutrophils from U-Grafts and LPS plugs. Primers were mouse specific 
(Supplementary Table 2). mRNA data are row-relative and normalized to ribosomal 18S 
rRNA. n = 3 mice per group. *** P < 0.001, ** P < 0.01, * P < 0.05 between U-Graft and 
LPS groups. (c) Representative Ly6G+ (red) neutrophils from U-Grafts and LPS plugs after 
exposure to gfp-E.coli (green). Phagocytosis of gfp-E.coli was visualized under a fluorescent 
microscope and quantified by flow cytometry. Bars represent normalized mean green 
fluorescence ± s.d. measured in gated Ly6G+ neutrophils; n = 3 mice per group. ** P < 0.01 
between U-Graft and LPS groups. (d) Macroscopic views of U-Grafts explanted at day 7 
from: (i) non-irradiated mice, (ii) irradiated mice, (iii) irradiated mice + transfer of BM-
LysM-Cre-neutrophils, (iv) irradiate mice + transfer of BM-tgfbr2−/− neutrophils, and (v) 
non-irradiated mice + TGF-β receptor inhibitor (SB432542). (e) H&E and (f) 
immunohistochemical (h-CD31+ cells) staining of U-Grafts explanted at day 7 from 
irradiated mice with transfer of either BM-LysM-Cre or BM-tgfbr2−/− neutrophils. Perfused 
vessels marked by yellow arrowheads. (g) Microvessel density at day 7. Bars represent mean 
± s.d.; n = 4 mice per group. *** P < 0.001, ** P < 0.01 compared to non-irradiated control 
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group. † P < 0.05 and †† P < 0.01 between indicated groups. (h–j) U-Grafts were implanted 
in mice treated with SB432542. Mice receiving saline injections served as controls. (h) H&E 
staining of explanted U-Grafts at day 7. (i) Immunofluorescent staining revealed the 
presence of human vessels (UEA-1+ lumen) and perivascular coverage (α-SMA+ cells) in 
the control group; and non-perfused human endothelial cord structures in SB432542-treated 
grafts. (j) Microvessel density quantified at day 7. Bars represent mean ± s.d.; n = 4 mice per 
group. * P < 0.05. Scale bars: 100 μm (e, f, h, i).
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Figure 5. Neutrophil activity regulated by secreted factors from the graft vasculature
(a) Schematic: daily samples of conditioned media (CM) collected from U-Grafts until they 
became A-Grafts. (b) H&E (left) and immunofluorescent (Ly6G, DAPI) staining revealing 
infiltration of neutrophils at day 2 into implanted Matrigel plugs containing CM from U-
Grafts. Left H&E inset corresponds to plug containing control basal medium (basal-M). (c) 
Flow cytometric quantification of neutrophil infiltration at day 2 into plugs containing CM 
collected at indicated times. Bars represent mean ± s.d.; n = 3 plugs per group. ** P < 0.01, 
* P < 0.05 compared to CM0–1. (d) Schematic of A-Grafts impregnated in CM from U-
Grafts and implanted into nude mice. (e) Flow cytometric quantification of neutrophil 
infiltration at day 2 into A-Grafts that were impregnated with and without CM(U-Graft). (f) 
H&E staining at day 7 of explanted A-Grafts that were impregnated with either CM(U-
Graft) or basal-M. Insets are macroscopic views of the explants. Perfused vessels marked by 
yellow arrowheads. (g) Microvessel density at day 7. Bars represent mean ± s.d.; n = 3 mice 
per group. ** P < 0.01. (h) Immunohistochemical staining (h-CD31+ cells) at day 7 in 
explanted A-Grafts that were impregnated with either CM(U-Graft) or basal-M. Perfused 
human h-CD31+ vascular structures were identified as lumens containing RBC. (i) Density 
of perfused human microvessels at day 7. Bars represent mean ± s.d.; n = 3 mice per group. 
*** P < 0.001, * P < 0.05 between indicated groups. Scale bars: 100 μm (b left, f, h), 50 μm 
(b right).
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Figure 6. Notch inhibition promotes A-Graft revascularization
(a) mRNA gene expression (qPCR) of NOTCH1 and downstream mediators of Notch 
signalling pathway (HEY1, HEY2, HES1, HES5). In vitro: data from ECFCs retrieved from 
U-Grafts and A-Grafts and normalized to ribosomal 18S rRNA. In vivo: data from total 
mRNA isolated from U-Grafts 30 min (day 0) and 7 days after implantation. Data 
normalized to human β-actin (ACTB). Bars represent mean ± s.d.; n = 3 grafts per group. 
*** P < 0.001, * P < 0.05. (b) Expression of CXCL1, CXCL8, and IL6 in ECFCs retrieved 
from U-Grafts and A-Grafts and normalized to ribosomal 18S rRNA. (c) Human cytokine 
protein array analysis of conditioned media (CM) from U-Grafts, A-Grafts, and A-Grafts + 
DAPT (γ-secretase inhibitor; 24 h exposure). Selected cytokines marked with color-lined 
boxes. Quantification of cytokine levels were carried out by densitometry. (d) Blocking 
neutrophil recruitment by neutralizing antibodies in subcutaneous plug assays. Neutralizing 
antibodies against IL6, CXCL8, and CXCL1 were added to CM(U-Grafts) prior to 
implantation. The number of neutrophils recruited into the plugs were measured by flow 
cytometry at day 2. Bars represent mean ± s.d.; n = 3–4 mice per group. *** P < 0.001 
compared to CM(U-Grafts). (e, f) Effect of CXCR2 antagonist (SB225002) on neutrophil 
recruitment and U-Graft vascularization. U-Grafts implanted in untreated mice served as 
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control. (e) Neutrophil recruitment into U-Graft at day 2 measured by flow cytometry. (f) 
Density of perfused microvessels at day 7. Bars represent mean ± s.d.; n = 3–6 mice per 
group. *** P < 0.001, ** P < 0.01 compared to Control. (g) Neutrophil recruitment at day 2 
in A-Grafts and A-Grafts + DAPT. Bars represent mean ± s.d.; n = 3–4 mice per group. * P 
< 0.05. (h) Macroscopic views of U-Grafts, A-Grafts, and A-Grafts + DAPT, explanted at 
day 7. (i) H&E and (j) immunohistochemical (h-CD31+ cells) staining of A-Grafts and A-
Grafts + DAPT explanted at day 7. Perfused vessels identified as luminal structures 
containing RBCs (yellow arrowheads). (k) Microvessel density at day 7. Bars represent 
mean ± s.d.; n = 4 mice per group. *** P < 0.001, * P < 0.05 between indicated groups. 
Scale bars: 50 μm.
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